potassium canrenoate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
477 2181-04-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • potassium canrenoate
  • aldadiene kalium
  • aldadiene potassium
  • canrenoate potassium
  • canrenoate
  • kanrenol
  • canrenoic acid
  • canrenoic acid potassium
  • canrenoic acid potassium salt
A synthetic pregnadiene derivative with anti-aldosterone activity.
  • Molecular weight: 358.48
  • Formula: C22H30O4
  • CLOGP: 3.16
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 2
  • TPSA: 74.60
  • ALOGS: -3.91
  • ROTB: 3

Drug dosage:

DoseUnitRoute
0.40 g P

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sopor 135.11 29.38 46 2598 22118 63464260
Hyperkalaemia 120.21 29.38 54 2590 54149 63432229
Lactic acidosis 97.29 29.38 42 2602 38245 63448133
Hyponatraemia 93.45 29.38 58 2586 111842 63374536
Drug interaction 92.09 29.38 76 2568 229055 63257323
Acute kidney injury 88.83 29.38 79 2565 263336 63223042
Syncope 64.60 29.38 47 2597 117338 63369040
Melaena 63.26 29.38 29 2615 30336 63456042
Toxic epidermal necrolysis 55.30 29.38 25 2619 25309 63461069
International normalised ratio increased 54.34 29.38 30 2614 46395 63439983
Metabolic acidosis 49.68 29.38 28 2616 45041 63441337
Bradycardia 48.81 29.38 33 2611 73194 63413184
Dehydration 44.84 29.38 45 2599 173309 63313069
Hyponatraemic syndrome 38.81 29.38 8 2636 547 63485831
Hyponatraemic encephalopathy 38.43 29.38 7 2637 249 63486129
Anaemia 34.37 29.38 51 2593 293379 63192999
Asthenia 33.10 29.38 58 2586 383546 63102832
Electrocardiogram QT prolonged 33.05 29.38 24 2620 59506 63426872
Hypoglycaemia 30.61 29.38 23 2621 60042 63426336

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperkalaemia 168.77 35.43 84 2155 69305 34885387
Hypotension 84.28 35.43 86 2153 221563 34733129
Sopor 73.30 35.43 28 2211 12108 34942584
Melaena 71.70 35.43 38 2201 35342 34919350
Drug interaction 68.78 35.43 78 2161 225868 34728824
Toxic epidermal necrolysis 66.91 35.43 31 2208 21615 34933077
Anaemia 66.73 35.43 78 2161 233257 34721435
Asthenia 60.35 35.43 76 2163 245175 34709517
Presyncope 54.88 35.43 26 2213 19033 34935659
Metabolic acidosis 46.54 35.43 31 2208 43649 34911043
Acute kidney injury 38.16 35.43 69 2170 304919 34649773

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperkalaemia 275.72 24.77 137 4873 114261 79625117
Sopor 185.97 24.77 72 4938 32938 79706440
Drug interaction 141.81 24.77 151 4859 415032 79324346
Melaena 129.05 24.77 67 4943 60823 79678555
Toxic epidermal necrolysis 114.83 24.77 56 4954 44525 79694853
Acute kidney injury 109.74 24.77 148 4862 519256 79220122
Hyponatraemia 103.31 24.77 87 4923 177761 79561617
Lactic acidosis 98.61 24.77 59 4951 70300 79669078
Metabolic acidosis 89.95 24.77 59 4951 82470 79656908
Anaemia 89.60 24.77 124 4886 444891 79294487
Asthenia 89.04 24.77 133 4877 511556 79227822
Syncope 80.72 24.77 76 4934 179373 79560005
Hypotension 63.32 24.77 105 4905 440212 79299166
Bradycardia 62.03 24.77 58 4952 135499 79603879
International normalised ratio increased 60.87 24.77 47 4963 84674 79654704
Presyncope 51.25 24.77 32 4978 41022 79698356
Oliguria 49.63 24.77 23 4987 16286 79723092
Dehydration 49.50 24.77 69 4941 248118 79491260
Electrocardiogram QT prolonged 41.94 24.77 39 4971 90347 79649031
Haematuria 34.46 24.77 31 4979 68805 79670573
Hyponatraemic encephalopathy 33.57 24.77 7 5003 333 79739045
Hyponatraemic syndrome 32.82 24.77 8 5002 772 79738606
Hypoglycaemia 32.75 24.77 36 4974 101558 79637820
Ascites 31.99 24.77 31 4979 75531 79663847
Rectal haemorrhage 29.88 24.77 30 4980 76270 79663108
Shock haemorrhagic 28.52 24.77 17 4993 20043 79719335
Loss of consciousness 28.07 24.77 43 4967 167900 79571478
Vascular parkinsonism 27.13 24.77 5 5005 124 79739254

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C03DA02 CARDIOVASCULAR SYSTEM
DIURETICS
ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS
Aldosterone antagonists
MeSH PA D004232 Diuretics
MeSH PA D006727 Hormone Antagonists
MeSH PA D000451 Mineralocorticoid Receptor Antagonists
MeSH PA D045283 Natriuretic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.78 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D01943 KEGG_DRUG
1981 RXNORM
CHEBI:50156 CHEBI
CHEMBL1371200 ChEMBL_ID
4138-96-9 SECONDARY_CAS_RN
DB09015 DRUGBANK_ID
318053000 SNOMEDCT_US
419615001 SNOMEDCT_US
C0006881 UMLSCUI
D002191 MESH_DESCRIPTOR_UI
CHEMBL1616951 ChEMBL_ID
23671691 PUBCHEM_CID
2448 INN_ID
2571 INN_ID
M671F9NLEA UNII
003944 NDDF
003945 NDDF

Pharmaceutical products:

None